Bengaluru, India

Parvinder Kaur

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Parvinder Kaur. Retrieved from https://idiyas.com/inventor/parvinder-kaur

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Parvinder Kaur: Innovator in Mycobacterial Treatment

Introduction

Parvinder Kaur is a notable inventor based in Bengaluru, India. He has made significant contributions to the field of medical science, particularly in the treatment of mycobacterial diseases. His innovative approach has led to the development of a unique patent that addresses critical health challenges.

Latest Patents

Parvinder Kaur holds a patent for "Mycobacterial inhibitors." This invention provides the use of certain succinimide compounds in the treatment of mycobacterial diseases. His work in this area is crucial for advancing therapeutic options for patients suffering from these conditions. He has 1 patent to his name.

Career Highlights

Parvinder is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Meenakshi Balganesh and Kantharaj Ethirajulu. Their collective expertise enhances the innovative environment at AstraZeneca, fostering advancements in medical treatments.

Conclusion

Parvinder Kaur's contributions to the field of mycobacterial treatment exemplify the impact of innovation in healthcare. His patent and work at AstraZeneca highlight the importance of research in developing effective therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…